Mesenchymal stem cell (MSC) chondrogenic differentiation pathways (MSC chondrogenesis)

Mesenchymal stem cell (MSC) chondrogenic differentiation pathways represent the coordinated signaling networks that drive the commitment and maturation of multipotent MSCs into chondrocytes, the primary cells of cartilage. This process is orchestrated by several key signaling families, most notably the Transforming Growth Factor-beta (TGF-beta) superfamily and Bone Morphogenetic Proteins (BMPs), which signal through SMAD proteins to activate the master chondrogenic transcription factor SOX9 [PubMed: 29051525, 30635253]. SOX9 subsequently induces the expression of essential cartilage matrix proteins, including Collagen type II and Aggrecan, while suppressing alternative lineages [PubMed: 30635253]. In clinical contexts, these pathways are critical for understanding and treating degenerative conditions like osteoarthritis, where chondrogenic signaling is often impaired or diverted toward a hypertrophic, bone-forming phenotype [PubMed: 31463455]. Therapeutic interventions, such as the administration of BMP-2 or small molecules like Kartogenin, aim to harness these pathways to promote cartilage repair and regeneration [PubMed: 28210544]. However, a significant challenge in targeting these pathways is preventing hypertrophy, a state where MSC-derived chondrocytes progress toward endochondral ossification, leading to calcified tissue rather than functional hyaline cartilage [PubMed: 25633134].

Other names

Chondrogenic differentiation of mesenchymal stem cellsMSC-to-chondrocyte differentiationCartilage differentiation signaling

Activation of SMAD2/3 and SMAD1/5/8 signaling, induction of SOX9 transcription factor, and modulation of Wnt/beta-catenin and MAPK pathways to promote cartilage-specific gene expression.